

# Against Lymphoma, I Take Action With LYSA

www.lysa-lymphoma.org

### LYSA

We are pleased to present LYSA (The Lymphoma Study Association), an academic cooperative group, which gathers every francophone medical team engaged in research on lymphoma. Over the last few years, many progresses have been accomplished for a better understanding of the development of this cancer (generally not well known by the general public), the improvement of diagnosis and treatments. Even if we are proud to have contributed to these results with our work, we are conscious of the way to go.

This is why, as we continue our structuration and collaborations, we have the ambition to develop a research at the forefront of medical and scientific innovations, and we hope that this will help us to reach better treatments for the patients tomorrow.

Pr Gilles Salles, President of LYSA





**To promote the activity** of our centers

**To provide** means and resources for research

**To organize** a professional network

**To promote** teaching and professional training

**To publish** in scientific papers with lecture committee

**To facilitate the communication** between researchers, physicians and patients

**To share** our results in national and international congresses

**To elaborate and lead** protocols for every stage of the disease

**To evaluate** new methods of patient management and new treatments

**To be a discussion partner** for national and international agencies, and medical societies



LYSARC

LYSARC, The Lymphoma Academic Research Organization, leads the researches approved by the LYSA Scientific board and Board of directors. More information on: www.lysarc.org, or contact@lysarc.org



#### LYSA-P, THE PATHOLOGY PLATFORM

Located in the Henri Mondor University Hospital (Créteil, France), LYSA-P gathers expert anatomopathologists around an operational structure for a centralized review of patient tumor samples and translational studies.

## LYSA-IM, THE IMAGING PLATFORM

Located in the Henri Mondor University Hospital (Créteil, France), LYSA-IM organizes a network of images review (PET, CT), and allows a real-time review of images for treatment decision-making (answers during treatment...).

#### LYSA-BIO, THE BIOLOGY PLATFORM

Located in the Henri Mondor University Hospital (Créteil, France), LYSA-BIO gathers all the technology for pre-analysis management of samples (DNA/RNA), and the real-time shipment to the analysis laboratories.

## EARLY, THE EARLY PHASE PLATFORM

An integrated organization between the trial centers and clinical research operations, to lead phase I/IIa studies, for first-in-human, first indication in lymphoma or first combination studies.

## **SCIENTIFIC ACTIVITIES OF LYSA**

#### **Trials: LYSARC, Sponsor of LYSA's Studies**

- From **phase I study**, including first-in-human, to phase **IV study**
- > Phase III studies, with the goal of registration
- More than 80 protocols over the last 10 years
- More than 1000 patients included in LYSA studies
- Anonymized, quality-controlled databases, for scientific promotion (translational studies, meta-analysis)
- A network of scientific experts and reference laboratories in the sectors of fundamental biology, hematopathology, imaging, bioinformatics, in order to promote clinical research works
- Participation in international consortiums to evaluate and validate new clinical or biological markers, in order to diagnose lymphoma and to monitor treatments efficacy

#### **Scientific Publications**

- Presentations in national (SFH...) and international congresses (ICML, ASCO, EHA, ASH...)
- Publications in international peer-review-journals
- Elaboration of national guidelines for a better patient care

#### **International Collaborations**

As a leader or a partner group, LYSA participates in **international academic** research in lymphoma.

#### **Collaborations with Industrials**

- LYSA/LYSARC cooperates with pharmaceutical industries and contributes, on the basis of scientific and clinical research expertise, to the **development** of new drugs. These formalized collaborations respect the independance of LYSA and LYSARC.
- LYSA conducts its research in accordance with the charter of relationships between the French Oncology Cooperative Groups (Les Groupes Coopérateurs en Oncologie, GCO - www.gco-cancer.org), coordination to which it belongs, and industry.

## **ENVIRONMENT** OF LYSA

#### Institutional Collaborations LYSA aims at being a privileged partner with all actors of lymphoma field.







Hospitals, universities and research institutions









GCO (Groupes Coopérateurs en Oncologie) is a French network of nine cooperative groups dedicated to cancer care that conduct clinical and translational research in France, Europe and other countries. Most of these groups are organ specific (e.g., lung, digestive, gynecologic, lymphoma, myeloma, head and neck, and brain cancers). Usually acting as study promotors and benefiting from their own operational resources, they have a strong track record of designing and completing trials that have diminished the impact of cancer in many ways. GCO also plays a strong science dissemination role through numerous publications in leading medical journals and presentations at the main oncology congresses. They are all nonprofit organizations and have been accredited "French cooperative intergroup of international dimension in the field of cancer." by the French National Cancer Institute (INCa). www.gco-cancer.org



The CALYM Carnot institute is an academic consortium that offers a unique R&D approach in lymphoma treatments and diagnosis spanning from new target identification to large international Phase III clinical trials and beyond. CALYM brings together 15 entities with complementary expertise in preclinical, translational and clinical lymphoma research: LYSA, LYSARC and 13 public research teams. www.calym.org

## **S**HIERAN INFO

ELI, The European Lymphoma Institute, gathers top European specialists in the lymphoma field within a network dedicated to research, training and education. To date, 13 European academic research groups have come together in an effort to define strategies to analyse and characterize this cancer, common diagnostic procedures and therapeutic standards as well as to facilitate clinical and fundamental research at the European level.

As a result of this collaborative work, truly unique in the world, ELI is helping to bring lymphoma research forward, and to guarantee equal access for all patients to the best possible care. www.eli.eu

## 130 LYSA Centers, Mainly in France and Belgium



#### How to Become a LYSA Member

The association is composed of members, who give an annual contribution, defined by the General Assembly.

Being a member allows you to participate in scientific meetings and manifestations and to have access to the member private section of LYSA's website.

The association is open to any professional who has his entire activity or part of it in the field of lymphoma, and who meets the association's objectives (excluding professionals whose main activity is in the industrial sector).

To become a member, you just need to send an e-mail to contact@lysa-lymphoma.org, with your motivations and a sponsor letter from a member of the association.

#### Head Office:

LYSA-CHU Lyon Sud Service hématologie Bât. IF F-69495 Pierre Bénite Cedex FRANCE

www.lysa-lymphoma.org Email: contact@lysa-lymphoma.org Twitter: @LysaLymphoma

#### LYSA's Endowment Funds

Through its missions, LYSA is willing that clinical and biological researches on lymphoma are led as close as possible to the patient needs. LYSA is a non-profit scientific research organization. By giving to the LYSA Endowment Funds for Research in Lymphoma, you are directly contributing to research programs, that have a chance to lead to real applications in healthcare.

http://www.lysa-lymphoma.org/en/ support-research/make-donation/